- Home
- TOVX
as 07-26-2024 4:00pm EST
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 4.0M | IPO Year: | 2006 |
| Target Price: | N/A | AVG Volume (30 days): | 135.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.20 - $0.70 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Theriva Biologics Inc. News
TOVX Breaking Stock News: Dive into TOVX Ticker-Specific Updates for Smart Investing
GuruFocus.com
2 months ago
Catherine Wood's Strategic Acquisition of PagerDuty Inc Shares
Business Wire
2 months ago
ADM Animal Nutrition Expands Recall to Include Additional Lots of Various Feed Products
GuruFocus.com
2 months ago
Insider Sale at Cogent Communications Holdings Inc (CCOI): CFO Thaddeus Weed Sells 2,400 Shares
Reuters
2 months ago
Factbox-Here's everything Apple announced at WWDC
Yahoo Finance Video
2 months ago
Elon Musk's Tesla pay package: More shareholders speak out
FreightWaves
2 months ago
Cargojet enters charter deal for Chinese e-commerce
CNW Group
2 months ago
Enghouse Releases Second Quarter Results
PR Newswire
2 months ago
AVENUE 8 DOUBLES DOWN ON GENERATIVE AI, SHIFTS FOCUS TO SIDEKICK PLATFORM FOR REAL ESTATE AGENTS
Compare TOVX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TOVX Theriva Biologics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.